PAXMAN publishes newsletter with information on its expanded FDA clearance and newly published, strong clinical results
PAXMAN has today published a new issue of its newsletter aimed at Swedish shareholders, investors and other interested parties.This issue highlights the company’s FDA clearance for solid tumours in the USA, the market approval in Mexico, progress in the approval process in Japan and recently published clinical studies where PAXMAN scalp cooling delivered very strong results. In addition to this, CEO Richard Paxman gives his impressions from the company’s attendance at ASCO, the world’s largest oncology conference. To read the newsletter (in Swedish only), and to subscribe, follow this